104 related articles for article (PubMed ID: 38941241)
21. Enhanced cellular uptake and intracellular drug controlled release of VESylated gemcitabine prodrug nanocapsules.
Fang Y; Du F; Xu Y; Meng H; Huang J; Zhang X; Lu W; Liu S; Yu J
Colloids Surf B Biointerfaces; 2015 Apr; 128():357-362. PubMed ID: 25746328
[TBL] [Abstract][Full Text] [Related]
22. Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs.
Galmarini CM; Warren G; Senanayake MT; Vinogradov SV
Int J Pharm; 2010 Aug; 395(1-2):281-9. PubMed ID: 20580798
[TBL] [Abstract][Full Text] [Related]
23. A biocompatible and cathepsin B sensitive nanoscale system of dendritic polyHPMA-gemcitabine prodrug enhances antitumor activity markedly.
Dai Y; Ma X; Zhang Y; Chen K; Tang JZ; Gong Q; Luo K
Biomater Sci; 2018 Nov; 6(11):2976-2986. PubMed ID: 30255871
[TBL] [Abstract][Full Text] [Related]
24. Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport.
Song X; Lorenzi PL; Landowski CP; Vig BS; Hilfinger JM; Amidon GL
Mol Pharm; 2005; 2(2):157-67. PubMed ID: 15804190
[TBL] [Abstract][Full Text] [Related]
25. Gemcitabine-camptothecin conjugates: a hybrid prodrug for controlled drug release and synergistic therapeutics.
Hou M; Xue P; Gao YE; Ma X; Bai S; Kang Y; Xu Z
Biomater Sci; 2017 Aug; 5(9):1889-1897. PubMed ID: 28681888
[TBL] [Abstract][Full Text] [Related]
26. Gemcitabine-coumarin-biotin conjugates: a target specific theranostic anticancer prodrug.
Maiti S; Park N; Han JH; Jeon HM; Lee JH; Bhuniya S; Kang C; Kim JS
J Am Chem Soc; 2013 Mar; 135(11):4567-72. PubMed ID: 23461361
[TBL] [Abstract][Full Text] [Related]
27. Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles.
Fan J; Fang G; Wang X; Zeng F; Xiang Y; Wu S
Nanotechnology; 2011 Nov; 22(45):455102. PubMed ID: 22019849
[TBL] [Abstract][Full Text] [Related]
28. Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue.
Gupta D; Varghese Gupta S; Dahan A; Tsume Y; Hilfinger J; Lee KD; Amidon GL
Mol Pharm; 2013 Feb; 10(2):512-22. PubMed ID: 23244438
[TBL] [Abstract][Full Text] [Related]
29. Gemcitabine-retinoid prodrug loaded nanoparticles display in vitro antitumor efficacy towards drug-resilient human PANC-1 pancreatic cancer cells.
Kakwere H; Ingham ES; Tumbale SK; Ferrara KW
Mater Sci Eng C Mater Biol Appl; 2020 Dec; 117():111251. PubMed ID: 32919625
[TBL] [Abstract][Full Text] [Related]
30. Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells.
Pratt SE; Durland-Busbice S; Shepard RL; Heinz-Taheny K; Iversen PW; Dantzig AH
Clin Cancer Res; 2013 Mar; 19(5):1159-68. PubMed ID: 23325581
[TBL] [Abstract][Full Text] [Related]
31. Novel anticancer polymeric conjugates of activated nucleoside analogues.
Senanayake TH; Warren G; Vinogradov SV
Bioconjug Chem; 2011 Oct; 22(10):1983-93. PubMed ID: 21863885
[TBL] [Abstract][Full Text] [Related]
32. The dipeptide monoester prodrugs of floxuridine and gemcitabine-feasibility of orally administrable nucleoside analogs.
Tsume Y; Borras Bermejo B; Amidon GL
Pharmaceuticals (Basel); 2014 Jan; 7(2):169-91. PubMed ID: 24473270
[TBL] [Abstract][Full Text] [Related]
33. Simultaneous determination of gemcitabine prodrug, gemcitabine and its major metabolite 2', 2'-difluorodeoxyuridine in rat plasma by UFLC-MS/MS.
Sun Y; Zhen L; Peng Y; Wang J; Fei F; Aa L; Jiang W; Pei X; Lu L; Liu J; Wang G; Hao K
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 May; 1084():4-13. PubMed ID: 29558739
[TBL] [Abstract][Full Text] [Related]
34. Syntheses and antitumor activities of potent inhibitors of ribonucleotide reductase: 3-amino-4-methylpyridine-2-carboxaldehyde-thiosemicarba-zone (3-AMP), 3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) and its water-soluble prodrugs.
Li J; Zheng LM; King I; Doyle TW; Chen SH
Curr Med Chem; 2001 Feb; 8(2):121-33. PubMed ID: 11172670
[TBL] [Abstract][Full Text] [Related]
35. Gemcitabine Based Peptide Conjugate with Improved Metabolic Properties and Dual Mode of Efficacy.
Karampelas T; Skavatsou E; Argyros O; Fokas D; Tamvakopoulos C
Mol Pharm; 2017 Mar; 14(3):674-685. PubMed ID: 28099809
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of gemcitabine and its amino acid ester prodrug following intravenous and oral administrations in mice.
Thompson BR; Shi J; Zhu HJ; Smith DE
Biochem Pharmacol; 2020 Oct; 180():114127. PubMed ID: 32603666
[TBL] [Abstract][Full Text] [Related]
37. In-vitro and in-vivo anti-cancer activity of a novel gemcitabine-cardiolipin conjugate.
Chen P; Chien PY; Khan AR; Sheikh S; Ali SM; Ahmad MU; Ahmad I
Anticancer Drugs; 2006 Jan; 17(1):53-61. PubMed ID: 16317290
[TBL] [Abstract][Full Text] [Related]
38. Improved plasma stability and sustained release profile of gemcitabine via polypeptide conjugation.
Kiew LV; Cheong SK; Sidik K; Chung LY
Int J Pharm; 2010 May; 391(1-2):212-20. PubMed ID: 20214970
[TBL] [Abstract][Full Text] [Related]
39. L-type amino acid transporter 1 utilizing prodrugs of ferulic acid revealed structural features supporting the design of prodrugs for brain delivery.
Puris E; Gynther M; Huttunen J; Auriola S; Huttunen KM
Eur J Pharm Sci; 2019 Mar; 129():99-109. PubMed ID: 30625368
[TBL] [Abstract][Full Text] [Related]
40. Multifunctional Tumor-Targeting Cathepsin B-Sensitive Gemcitabine Prodrug Covalently Targets Albumin in Situ and Improves Cancer Therapy.
Zhang H; Sun Z; Wang K; Li N; Chen H; Tan X; Li L; He Z; Sun J
Bioconjug Chem; 2018 Jun; 29(6):1852-1858. PubMed ID: 29775284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
